Rigel Pharmaceuticals, Inc.
RIGL
$17.88
-$0.73-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -7.40% | 4.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.40% | 4.14% | |||
| Cost of Revenue | 12.47% | -19.62% | |||
| Gross Profit | -12.32% | 12.35% | |||
| SG&A Expenses | -6.11% | 9.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.93% | -0.75% | |||
| Operating Income | -23.31% | 18.49% | |||
| Income Before Tax | -24.38% | 22.55% | |||
| Income Tax Expenses | -92.62% | -- | |||
| Earnings from Continuing Operations | -20.19% | 15.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.19% | 15.46% | |||
| EBIT | -23.31% | 18.49% | |||
| EBITDA | -22.49% | 17.67% | |||
| EPS Basic | -20.92% | 15.16% | |||
| Normalized Basic EPS | -25.06% | 22.22% | |||
| EPS Diluted | -20.99% | 13.91% | |||
| Normalized Diluted EPS | -25.14% | 20.25% | |||
| Average Basic Shares Outstanding | 0.91% | 0.27% | |||
| Average Diluted Shares Outstanding | 1.02% | 1.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||